Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
Aardvark Therapeutics Inc. (NASDAQ:AARD) is one of the best young stocks with huge upside potential.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 3,917,299 | $52,060,903 | 9.08% | |
| 2. | Citadel Investment Group Ken Griffin | 1,359,883 | $18,072,846 | +6% | 0% |
| 3. | Laurion Capital Management Benjamin A. Smith | 1,049,721 | $13,950,792 | +7% | 0.24% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 350,000 | $4,651,500 | +100% | 0.01% |
| 5. | Millennium Management Israel Englander | 319,623 | $4,247,790 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.94 | 3,500 | $34,804.70 | 1,543,384 | 2025-09-15 | Filing | |
| $9.51 | 6,500 | $61,818.90 | 1,539,884 | 2025-09-15 | Filing | |
| $8.50 | 5,000 | $42,515.50 | 1,533,384 | 2025-09-12 | Filing | |
| $7.82 | 6,000 | $46,926.00 | 1,528,384 | 2025-09-11 | Filing | |
| $7.91 | 9,000 | $71,212.50 | 1,522,384 | 2025-09-10 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 555,721 | $7,385,532 | 0% | |
| 2. | 309,465 | $4,112,790 | 0% | |
| 3. | 194,035 | $2,578,990 | 0% | |
| 4. | 146,783 | $1,950,746 | 0.01% | |
| 5. | 93,005 | $1,236,036 | 0% |